B
BioAtla D
D
BCAB
1.63500
USD
0.08
(4.81%)
Market Closed
Volume
10,789
EPS
-1
Div Yield
-
P/E
-1
Market Cap
79,045,012
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: BioAtla
Sector: Healthcare
Industry: Biotechnology
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.